Open Access<p>Targeting Prostate Cancer Using Intratumoral Cytotopically Modified Interleukin-15 Immunotherapy in a Syngeneic Murine Model</p>
Author(s) -
Efthymia Papaevangelou,
Dorota Smolarek,
Roger Smith,
Prokar Dasgupta,
Christine Galustian
Publication year - 2020
Publication title -
immunotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.256
H-Index - 7
ISSN - 2253-1556
DOI - 10.2147/itt.s257443
Subject(s) - prostate cancer , immunotherapy , medicine , cancer research , cancer immunotherapy , interleukin 2 , interleukin 15 , cancer , interleukin , immunology , cytokine
The prostate cancer microenvironment is highly immunosuppressive; immune cells stimulated in the periphery by systemic immunotherapies will be rendered inactive once entering this environment. Immunotherapies for prostate cancer need to break this immune tolerance. We have previously identified interleukin-15 (IL-15) as the only cytokine tested that activates and expands immune cells in the presence of prostate cancer cells. In the current study, we aimed to identify a method of boosting the efficacy of IL-15 in prostate cancer.